Video

'Maximum Amount of Caution' Necessary for Immunosuppressed Patients Amid COVID-19 Pandemic

In the face of the COVID-19 pandemic patients with cancer who are considered to have weakened immune systems need to have a special emphasis placed on their care.

With the COVID-19 pandemic sweeping the world, patients with cancer face another challenge as many are considered to have weakened immune systems, potentially leaving them vulnerable to deal with a coronavirus infection.

At the 37th Annual Miami Breast Cancer Conference OncLive®, a sister publication to CURE®, sat down with Dr. Patrick Borgen, director of the breast cancer program at the Maimonides Medical Center in Brooklyn, New York, and discussed the importance of immune suppressed patients taking extra precautions during their care amid the spread of the virus.

TRANSCRIPTION

And so right now we're in a very scary place. A number of institutions chose to have travel restrictions on their faculty. I totally get that. And one of the things that seems to be clear about COVID-19, is that it is really dangerous for immunosuppressed patients. And we do a lot of immune suppression in the cancer treatment world. And so, having a maximum amount of care and caution is the right thing for us to be doing right now.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.